A Wrinkle in the Botox Plan

Allergan NYSE: AGN is trying to expand the use of its anti-wrinkle drug, Botox, but the Food and Drug Administration threw a wrinkle into its plan yesterday by turning down Allergan’s application to market Botox for upper limb spasticity — a disorder that causes muscles to tighten. Getting a complete response letter is rarely a good thing, but it wasn’t all bad news for Allergan.

Read full story via Fool.com

Short URL: http://www.plasticsurgeonsnews.com/?p=265

Posted by admin on May 28 2009. Filed under Injectables. You can follow any responses to this entry through the RSS 2.0. You can leave a response or trackback to this entry